These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21410419)

  • 1. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.
    Allay JA; Sleep S; Long S; Tillman DM; Clark R; Carney G; Fagone P; McIntosh JH; Nienhuis AW; Davidoff AM; Nathwani AC; Gray JT
    Hum Gene Ther; 2011 May; 22(5):595-604. PubMed ID: 21410419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.
    Grieger JC; Soltys SM; Samulski RJ
    Mol Ther; 2016 Feb; 24(2):287-297. PubMed ID: 26437810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.
    Hauck B; Xu RR; Xie J; Wu W; Ding Q; Sipler M; Wang H; Chen L; Wright JF; Xiao W
    Hum Gene Ther; 2006 Jan; 17(1):46-54. PubMed ID: 16409124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and improved AAVenues: current status of hemophilia B gene therapy.
    Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
    Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for hemophilia: advancing beyond the first clinical success.
    Monahan PE; Gui T
    Curr Opin Hematol; 2013 Sep; 20(5):410-6. PubMed ID: 23852185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography.
    Lock M; Alvira MR; Wilson JM
    Hum Gene Ther Methods; 2012 Feb; 23(1):56-64. PubMed ID: 22428980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.
    Markusic DM; Herzog RW; Aslanidi GV; Hoffman BE; Li B; Li M; Jayandharan GR; Ling C; Zolotukhin I; Ma W; Zolotukhin S; Srivastava A; Zhong L
    Mol Ther; 2010 Dec; 18(12):2048-56. PubMed ID: 20736929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV-mediated gene transfer for hemophilia.
    High KA
    Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
    Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
    Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
    Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
    Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver.
    Lu H; Qu G; Yang X; Xu R; Xiao W
    Hum Gene Ther; 2011 May; 22(5):625-32. PubMed ID: 21244243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.